EASD 2025 - Semaglutide was seen to reduce the risk of major adverse limb events (MALE) in diabetes patients.

Dr Subodh Verma (University of Toronto, Toronto, CA) joins us to discuss findings from a pooled analysis of 13,975 participants from the SOUL, FLOW and STRIDE randomised trials investigating the effects of semaglutide on risk reduction of MALE in diabetes.

Findings showed semaglutide reduced the time to first adjudicated confirmed MALE by 30%, and semaglutide was also seen to reduce MALE regardless of prevalence of peripheral artery disease at baseline. Additionally, a risk reduction in adjudicated acute limb ischemia (ALI) and chronic limb ischemia (CLI) hospitalisations were seen.

Recorded virtually from Toronto, 2025.

Editors: Jordan Rance, Yazmin Sadik.
Videographers: Tom Green, David Ben-Harosh.
Support: This is an independent interview produced by Radcliffe CVRM.